|
| Product Name: | ABT-492 MegluMine | | Synonyms: | 100850;ABT 492 meglumine (Delafloxacin meglumine);Delafloxacin meglumine (ABT492 meglumine;(2R,3R,4R,5S)-2,3,4,5-tetrahydroxy-6-(MethylaMino)hexyl 1-(6-aMino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;ABT 492 MegluMine;ABT492 MegluMine;ABT-492 MegluMine;Delafloxacin (MegluMine) | | CAS: | 352458-37-8 | | MF: | C25H29ClF3N5O9 | | MW: | 635.98 | | EINECS: | | | Product Categories: | API | | Mol File: | 352458-37-8.mol |  |
| | ABT-492 MegluMine Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | Soluble in DMSO | | form | Powder |
| | ABT-492 MegluMine Usage And Synthesis |
| Physical Form | Solid | | Description | Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials. | | Uses | Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa. | | Biological Activity | Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine is a broad spectrum fluoroquinolone antibiotic. Delafloxacin has a wide range of activity against drug-resistant Staphylococcus aureus, Streptococcus pneumoniae and Klebsiella pneumoniae. |
| | ABT-492 MegluMine Preparation Products And Raw materials |
|
